Treatment of Established Relapsing Experimental Autoimmune Encephalomyelitis with the Proteasome Inhibitor PS-519¹

By vanderlugt C.L.   Rahbe S.M.   Elliott P.J.   Dal Canto M.C.   Miller S.D.  

Journal of Autoimmunity, Vol. 14, Iss. 3, 2000-05 ,pp. : 205-211

Academic Press

Access to resources Recommend Favorite

Complexities in the development of cyclin-dependent kinase inhibitor drugs

By Sausville E.A.  

Trends in Molecular Medicine, Vol. 8, Iss. 4, 2002-04 ,pp. : 32-37

Elsevier

Access to resources Recommend Favorite

Proteasome inhibitor bortezomib overcomes P‐gp‐mediated multidrug resistance in resistant leukemic cell lines

By  

International Journal Of Laboratory Hematology, Vol. 34, Iss. 3, 2012-06 ,pp. : 237-247

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanistic Basis for Site–Site Interactions in Inhibitor and Substrate Binding to Band 3 (AE1): Evidence Distinguishing Allosteric from Electrostatic Effects

By Salhany J.M.  

Blood Cells, Molecules, and Diseases, Vol. 27, Iss. 5, 2001-05 ,pp. : 901-912

Academic Press

Access to resources Recommend Favorite

Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema

By Craig Timothy   Wasserman Richard   Levy Robyn   Bewtra Againdra   Schneider Lynda   Packer Flint   Yang William   Keinecke Heinz-Otto   Kiessling Peter  

Journal of Clinical Immunology, Vol. 30, Iss. 6, 2010-11 ,pp. : 823-829

Springer Publishing Company

Access to resources Recommend Favorite